| 36th week of 2022 patent applcation highlights part 8 |
| Patent application number | Title | Published |
|---|
| 20220280396 | WATER-IN-OIL EMULSION COMPOSITION - A water-in-oil emulsion composition includes (a) at least one ascorbic acid phosphate ester compound selected from the group consisting of ascorbic acid phosphate esters and salts thereof, (b) an organically modified clay mineral, (c) an oil-based agent, and (d) water, in which a content of the component (b) is 0.2% by mass to 4.5% by mass. | 2022-09-08 |
| 20220280397 | ELECTROMAGNETIC RADIATION AND DELIVERY CARRIER FOR ORAL CARE - Delivery carriers having multi-phase oral compositions used with an electromagnetic radiation source for whitening teeth. | 2022-09-08 |
| 20220280398 | METHOD FOR MANUFACTURING MICROCAPSULES CONTAINING A LIPOPHILIC ACTIVE INGREDIENT, MICROCAPSULES PREPARED BY SAID METHOD AND THE USE THEREOF - The present invention relates to a process for manufacturing reservoir-type microcapsules containing a lipophilic active agent, the wall of which comprises at least two polymers obtained by co-crosslinking of a polymer obtained by complex coacervation and of a copolymer of silicone, melamine-carbamate and polyurethane. The microcapsules thus prepared may be used in formulations containing surfactants, such as washing products or detergents, or in cosmetic formulations such as shampoos or soaps. | 2022-09-08 |
| 20220280399 | NON-OXIDATIVE HAIR DYE COMPOSITION AND METHOD - The present invention is directed to a non-oxidative dyeing composition, method, and use for hair. The composition comprises certain direct dyes, fatty alcohols, surfactants, and a buffer system. | 2022-09-08 |
| 20220280400 | SUNSCREEN COMPOSITIONS CONTAINING A COMBINATION OF A LINEAR ULTRAVIOLET RADIATION-ABSORBING POLYETHER AND OTHER ULTRAVIOLET-SCREENING COMPOUNDS - Sunscreen composition including a combination of a linear ultraviolet radiation absorbing polyether that includes a covalently bound UV-chromophore, and at least one non-polymeric UV-screening compounds. | 2022-09-08 |
| 20220280401 | AN ANTIDANDRUFF COMPOSITION - Disclosed is an antidandruff composition comprising low amounts of piroctone olamine which synergistically interacts with benzoic acid or a salt thereof and itaconic acid or an ester thereof. The composition may be used for personal cleansing and is especially preferred to be delivered as a shampoo or hair conditioner. | 2022-09-08 |
| 20220280402 | ALIPHATIC ANIONIC COMPOUNDS AND OXIDATIVE COMPOUNDS WITH IMPROVED STABILITY AND EFFICACY FOR USE IN PHARMACEUTICAL COMPOSITIONS - Various embodiments described herein provide for a multi-component compositions and methods for its pharmaceutical and cosmetic use, comprising a combination of an aliphatic anionic compound, an oxidative compound, and a buffering system. Source of fluoride ion and other carriers are optional ingredients. The aliphatic anionic compound and the oxidative compound function together, in presence or absence of fluoride ion source, to protect the oxidative compounds from degradation prior to use and upon use, and to enhance the efficacy of the composition. In addition to achieving greater stability, combined effects of the aliphatic anionic compound, oxidative compound and source of fluoride ion achieve enhanced fluoride uptake, higher enamel protection by enhanced remineralization and reduced demineralization, increased plaque removal, reduced re-growth of plaque polymicrobial biofilm, greater amount of chlorite ion availability and effective oxidation of salivary biomolecules. | 2022-09-08 |
| 20220280403 | Method to Incorporate Oleanolic Acid into Oral Care Compositions and Oral Care Compositions Based Thereof - An aqueous oleanolic acid solution, including from about 0.10 to 2.5 weight % oleanolic acid, from about 60 to 90 weight % solvent, and from about 20 to 40 weight % solubility agent, wherein the solvent includes water, the solubility agent includes sodium lauryl sulfate (SLS), and the aqueous oleanolic acid solution is substantially free of ethanol and dimethyl sulfoxide (DMSO). | 2022-09-08 |
| 20220280404 | HAIR COSMETIC - A hair cosmetic containing the following components (A) and (B), wherein a mass ratio of the component (B) to the component (A), (B)/(A), is 0.25 or more and 1.90 or less:
| 2022-09-08 |
| 20220280405 | NOVEL COMPOUNDS FOR SKIN LIGHTENING - A novel compound is disclosed. Skin lightening composition comprising said compound and method of skin lightening is disclosed too. In addition, method of synthesizing said novel compound is disclosed. | 2022-09-08 |
| 20220280406 | METHOD FOR DYEING KERATINOUS MATERIAL, COMPRISING THE USE OF AN ORGANOSILICON COMPOUND, A COLORED EFFECT PIGMENT AND A SEALING REAGENT III - The subject of the present disclosure is a process for dyeing keratinous material, in particular human hair, comprising the following steps:
| 2022-09-08 |
| 20220280407 | METHOD FOR TREATING KERATIN MATERIAL, COMPRISING THE USE OF AN ORGANIC C1-C6-ALKOXY-SILANE AND AN AMINO ACID AND/OR AN AMINO ACID DERIVATIVE - It is an object of the present disclosure is to provide a method for treating keratinous material, in particular human hair, wherein on the keratinous material are applied:
| 2022-09-08 |
| 20220280408 | ORGANIC COMPOUNDS - A cosmetic ingredient comprising crenatoside and acteoside when applied to the skin is useful to provide cosmetic and perfumery benefits. | 2022-09-08 |
| 20220280409 | MOLDABLE COMPOSITION FOR SOLID WASHING AGENT AND METHOD FOR MOLDING THE SAME - The present disclosure is directed to providing a moldable solid washing agent composition and an article molded from the same. The composition of the present disclosure can be stored easily at room temperature for a long time. It is applicable to a system that can be manufactured on site and can satisfy customer needs because it can be molded immediately by a simple method and the shape, size, etc. can be controlled. In addition, the solid washing agent composition disclosed in the present specification has superior compatibility with water. | 2022-09-08 |
| 20220280410 | COSMETIC COMPOSITION COMPRISING AN ORAL CAPSULE CONTAINING HYALURONIC ACID AND WHEAT GRAIN OIL WITH PHYTOCERAMIDES - A capsule for oral administration, comprising: a filling having from 30 to 50% by weight hyaluronic acid; and from 55 to 65% by weight of a wheat grain extract oil comprising phytoceramides. The phytoceramides are present in the capsule in an amount of from 0.1 to 5% by weight. The % by weight of each component is measured relative to the total combined weight of the hyaluronic acid and wheat grain extract oil. Also related methods, uses and further products. | 2022-09-08 |
| 20220280411 | Mattifying Cosmetic Compositions - Mattifying single phase cosmetic compositions that are flexible and resistant to water below a selected temperature, 43° C. for example. The compositions wear well, are smudge and flake resistant, as well as oil resistant. Compositions according to the invention comprise specific combinations of acrylates/VA copolymer, acrylates copolymer and HDI/trimethylol hexyllactone crosspolymer/silica in a cosmetically acceptable base or delivery vehicle. Compositions according to the invention are hydrophilic before application, but dry to a clear hydrophobic film. The dried film can be easily removed when scrubbed with water above a certain temperature, but not as easily removed with water below that temperature. The compositions are easy to manufacture, flexible and comfortable, and suitable for use on skin and hair. | 2022-09-08 |
| 20220280412 | POLYMER COATING AGENT HAVING CONCURRENTLY EXCELLENT WATER AND OIL REPELLENT PROPERTIES AND COSMETIC COMPOSITION COMPRISING SAME SHOWING EXCELLENT MAKE-UP PERSISTENCY - The present disclosure relates to a film-forming polymer with both of excellent water-repellent and oil-repellent properties and a cosmetic composition with excellent long-lasting property comprising the same. The film-forming polymer and cosmetic composition comprising the same according to the present disclosure increase the durability of makeup, so that even after a long period of time, numbers of correction makeup are reduced or does not need to be corrected. | 2022-09-08 |
| 20220280413 | WETTING COMPOSITION INCLUDING SILICONE POLYMER SOFTENING AGENT AND WET WIPES INCLUDING THE SAME - Wetting compositions can include water and a silicone-based softening agent. The softening agent can include a structure of: G | 2022-09-08 |
| 20220280414 | COSMETIC SKIN HYDRATION COMPLEX, USE OF THE COSMETIC COMPLEX, COSMETIC COMPOSITION AND METHOD FOR SKIN HYDRATION - The present invention relates to a cosmetic complex that provides simultaneous skin hydration benefits, as well as its use for the preparation of a cosmetic composition. Said complex comprises the combination of cocoa butter ( | 2022-09-08 |
| 20220280415 | STABILIZER CONCENTRATES FOR WAX DISPERSIONS - This invention relates to stabilizer concentrates which improve the stability of mono- and/or diesters of mono- and/or diethylene glycol waxes, which are inform of a wax dispersion in personal care compositions, wherein the stabilizer concentrates comprising hydrogenated castor oil and selected non-ionic emulsifiers, especially alkyl poly glucosides, and are free of anionic surfactants. | 2022-09-08 |
| 20220280416 | COSMETIC COMPOSITIONS AND METHODS OF THEIR USE - Described herein are compositions useful for moisturizing and/or improving the appearance of skin by evening skin tone and/or reducing the appearance of dark spots or hyperpigmentation. The compositions comprise cosmetic ingredients such as | 2022-09-08 |
| 20220280417 | Antipsychotic Injectable Depot Composition - The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks. | 2022-09-08 |
| 20220280418 | ORAL PHARMACEUTICAL COMPOSITION - Provided is a means that is capable of preventing initial excessive release of an active ingredient and that allows for sustained release of the active ingredient in a pharmaceutically active amount over a long period of time. | 2022-09-08 |
| 20220280419 | DEEP TOPICAL SYSTEMIC NITRIC OXIDE THERAPY APPARATUS AND METHOD - A topical mixture that produces nitric oxide and a method for using the topical mixture to increase the vasodilation of a bloodstream via transdermal absorption of the nitric oxide. The nitric oxide can then affect subcutaneous tissues. The systemic vasodilation of a mammal may be increased via a topical application of an appropriate nitric oxide producing substance. | 2022-09-08 |
| 20220280420 | DEEP TOPICAL SYSTEMIC NITRIC OXIDE THERAPY APPARATUS AND METHOD - A topical mixture that produces nitric oxide and a method for using the topical mixture to increase the vasodilation of a bloodstream via transdermal absorption of the nitric oxide. The nitric oxide can then affect subcutaneous tissues. The systemic vasodilation of a mammal may be increased via a topical application of an appropriate nitric oxide producing substance. | 2022-09-08 |
| 20220280421 | AQUEOUS SUSPENSION SUITABLE FOR ORAL ADMINISTRATION - The present invention provides liquid oral dosage form of lipid lowering agent suitable for oral administration to human or animals. | 2022-09-08 |
| 20220280422 | SOLUBILIZED MELATONIN - A method of making an orally-dissolvable strip includes combining melatonin with glycerin, forming a melatonin solution by heating the combined melatonin and glycerin to dissolve the melatonin in the glycerin, and forming a plurality of liposomes by mixing a liposomal base with the melatonin solution. Each liposome of the plurality of liposomes includes a lipid shell of the liposomal base encapsulating a portion of the melatonin solution. The method further includes forming the orally-dissolvable strip by combining the plurality of liposomes with a base material. The base material and the liposomal base are orally-dissolvable. The lipid shell prevents crystallization of the dissolved melatonin in the glycerin, such that within each liposome of the plurality of liposomes the melatonin is dissolved in the glycerin. | 2022-09-08 |
| 20220280423 | GLYMPHATIC DELIVERY BY MANIPULATING PLASMA OSMOLARITY - This invention relates to improving delivery of agents (e.g., one or more nanoparticles) to the central nervous system. | 2022-09-08 |
| 20220280424 | METHOD AND COMPOSITION FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS - Pharmaceutical compositions for preventing or reducing kidney injury are disclosed, where the pharmaceutical compositions include (1) siRNAs non-covalently conjugated to functionalized single walled carbon nanotubes (f-SWCNTs) and (2) a pharmaceutically acceptable carrier, where the siRNAs inhibit expression of one or more genes selected from the group consisting of MEP1B and p53 genes. | 2022-09-08 |
| 20220280425 | FLAVONOIDS AND LINOLEIC ACID USES IN HYPERTENSION - Methoxylated flavonoids are described for their compositions and uses in hypertension treatment as vasodilators. The flavonoids are intravenously administered in a self-nanoemulsifying drug delivery system (SNEDDS) in combination with linoleic acid which provides lowering heart rate, thus suppressing reflex tachycardia elicited by the vasodilating effect of flavonoids. The compositions are used to treat or prevent acute hypertension or any acute symptoms of emergency hypertension. | 2022-09-08 |
| 20220280426 | COMPOSITIONS OF BUPIVACAINE MULTIVESICULAR LIPOSOMES - Embodiments of the present application relate to compositions of multivesicular liposomes (MVLs) and manufacturing processes for making bupivacaine MVLs. | 2022-09-08 |
| 20220280427 | LIPID NANOPARTICLE COMPOSITIONS COMPRISING CLOSED-ENDED DNA AND CLEAVABLE LIPIDS AND METHODS OF USE THEREOF - Provided herein are lipid formulations comprising a lipid and a capsid free, non-viral vector (e.g. ceDNA). Lipid particles (e.g., lipid nanoparticles) of the invention include a lipid formulation that can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like). | 2022-09-08 |
| 20220280428 | TUNABLE LEUKOCYTE-BASED BIOMIMETIC NANOPARTICLES AND METHODS OF USE - Disclosed are liposomal formulations and biomimetic proteolipid nanoparticles that possess remarkable properties for targeting compounds of interest to particular mammalian cell and tissue types. Leukocyte-based biomimetic nanoparticles are disclosed that incorporate cell membrane proteins to transfer the natural tropism of leukocytes to the final delivery platform. However, tuning the protein integration can affect the in vivo behavior of these nanoparticles and alter their efficacy. Here it is shown that, while increasing the protein:lipid ratio to a maximum of 1:20 (w/w) maintained the nanoparticle's structural properties, increasing protein content resulted in improved targeting of inflamed endothelium in two different animal models. The combined use of a microfluidic, bottom-up approach and tuning of key synthesis parameter enabled the synthesis of reproducible, enhanced biomimetic nanoparticles that have the potential to improve treatment of inflammatory-based conditions through targeted nanodelivery, including particular cancers such as human breast cancer, and TNBC in particular. | 2022-09-08 |
| 20220280429 | Tunable leukocyte-based biomimetic nanoparticles and methods of use - Disclosed are liposomal formulations and biomimetic proteolipid nanoparticles that possess remarkable properties for targeting compounds of interest to particular mammalian cell and tissue types. Leukocyte-based biomimetic nanoparticles are disclosed that incorporate cell membrane proteins to transfer the natural tropism of leukocytes to the final delivery platform. However, tuning the protein integration can affect the in vivo behavior of these nanoparticles and alter their efficacy. Here it is shown that, while increasing the protein:lipid ratio to a maximum of 1:20 (wt./wt.) maintained the nanoparticle's structural properties, increasing protein content resulted in improved targeting of inflamed endothelium in two different animal models. The combined use of a microfluidic, bottom-up approach, and the tuning of key synthesis parameters enabled the synthesis of reproducible, biomimetic nanoparticles for the improved targeted nanodelivery of a variety of inflammatory-based conditions, including particular cancers such as human breast cancer, and TNBC, in particular. | 2022-09-08 |
| 20220280430 | TREPROSTINIL DERIVATIVES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS - Provided are treprostinil derivatives with a reduced ability to form undesired impurities in a pharmaceutical formulation, such as a dry powder formulation, further containing a carboxyl group containing inactive ingredient, such as fumaryl diketopiperazine. | 2022-09-08 |
| 20220280431 | CURCUMIN COMPLEX, PREPARATION METHOD THEREFOR AND DETECTION METHOD THEREFOR - A curcumin complex, a preparation method therefor and a detection method therefor, the curcumin complex comprising a solid complex formed by grinding auxiliary material and curcumin, the auxiliary material comprising Soluplus, poloxamer 407, or poloxamer 188; when the auxiliary material comprises the Soluplus, the mass ratio of the curcumin to the Soluplus is 1:8-10; and when the auxiliary material comprises the poloxamer 407 or poloxamer 188, the mass ratio of the curcumin to the poloxamer 407 is 1:0.4-0.6, and the mass ratio of the curcumin to the poloxamer 188 is 1:0.4-0.6. Also disclosed is a preparation method for a curcumin complex. The curcumin complex has high bioavailability and a simple prescription process; in addition, the crystal form of the curcumin is not changed, and not only is quality control more complete and reliable, but costs are also lower, and large-scale production is facilitated. | 2022-09-08 |
| 20220280432 | METHOD FOR CONTINUOUSLY PRODUCING AN ACTIVE INGREDIENT GRANULATE - A method for the continuous production of an active ingredient granulate is provided, which comprises the following steps:
| 2022-09-08 |
| 20220280433 | STABLE LOW DIGESTIVE ENZYME CONTENT FORMULATION - The present invention is directed to a pharmaceutical composition or dosage form having a stable, low (diluted) digestive enzyme content comprising at least one digestive enzyme and at least one carrier, or a dosage form thereof. The invention is also directed to a process of preparation of the composition or the dosage form. In addition the invention is directed to the treatment and prevention of disorders or conditions associated with a digestive enzyme deficiency in a patient in need thereof, comprising administering to said patient a pharmaceutically acceptable amount of the composition having a stable low digestive enzyme content or dosage form thereof. | 2022-09-08 |
| 20220280434 | RAPIDLY DISINTEGRATING GELATINOUS COATED TABLETS - The present invention relates to an improved gelatinous coated dosage form having two end regions coated with gelatinous materials and an exposed circumferential band. Openings are provided in at least the exposed band to reveal the core material. The invention also relates to methods for manufacturing such gelatinous coated dosage forms. | 2022-09-08 |
| 20220280435 | COMPONENTS WITH HIGH API LOADING - Components with relatively high loading of active pharmaceutical ingredients (e.g., drugs), are generally provided. In some embodiments, the component (e.g., a tissue interfacing component) comprises a solid therapeutic agent (e.g., a solid API) and a supporting material (e.g., a binder such as a polymer) such that the solid therapeutic agent is present in the component in an amount of greater than or equal to 10 wt % versus the total weight of the tissue interfacing component. Such tissue-interfacing components may be useful for delivery of API doses e.g., to a subject. Advantageously, in some embodiments, the reduction of volume required to deliver the required API dose as compared to a liquid formulation permits the creation of solid needle delivery systems for a wide variety of drugs in a variety of places/tissues (e.g., tongue, GI mucosal tissue, skin) and/or reduces and/or eliminates the application of an external force in order to inject a drug solution through the small opening in the needle. In some cases, a physiologically relevant dose may be present in a single tissue interfacing component (e.g., having a relatively high API loading). | 2022-09-08 |
| 20220280436 | SOFTSHELL CAPSULE FORMULATIONS, AND METHODS OF PREPARATION AND USE THEREOF - Disclosed herein are softgel dosage forms, for example, stable aspirin softgel capsules. Also disclosed herein are methods of preparing such softgel dosage forms and methods of use thereof. | 2022-09-08 |
| 20220280437 | FORMULATION - Provided is a formulation that can improve all of transdermal absorbability of an active ingredient, immediate effect in transdermal absorption, and reduction of skin irritation, to high levels. A formulation containing: a base; and a core-shell structure having a core portion containing an active ingredient and a shell portion containing a surfactant; in which the core portion is a solid, the surfactant contains a compound having two or more fatty acid bonds and a compound having one fatty acid bond, and a proportion of the compound having two or more fatty acid bonds in the surfactant is 5% by weight or more and 75% by weight or less. | 2022-09-08 |
| 20220280438 | MEMBRANE LIPID COATED NANOPARTICLES AND METHOD OF USE - Disclosed is a nanoparticle comprising an inner core comprising a virus; and an outer surface comprising a cellular membrane derived from a cell, and process of making thereof. The virus is an oncolytic virus and cellular membrane is derived from for example red blood cells. | 2022-09-08 |
| 20220280439 | METHODS FOR LOWERING THE INFECTION RATE OF VIRUSES - According to some embodiments, a method of reducing a likelihood of a pathogen binding to cell structures of a host comprises at least partially blocking the pathogen from binding to cell structures of the host as a result of competitive inhibition by delivering a carrier to the host, and at least partially reducing the likelihood of the pathogen binding to target areas of cell structures of the host. | 2022-09-08 |
| 20220280440 | METHOD FOR THE MANUFACTURE OF A DOSAGE FORM WITH MUCOADHESIVE PROPERTIES FOR BUCCAL ADMINISTRATION OF BIOLOGICS - The invention relates to the pharmaceutical industry, particularly to the pharmaceutical industry related to biological drugs, biomacromolecules, biopharmaceuticals, or biologics. More particularly, the invention relates to a method for the manufacture of a highly controlled and stable dosage form with mucoadhesive properties for buccal administration of biologics such as lymphokines, hormones, hematopoietic factors, growth factors, antibodies, enzymes, inhibitors, vaccines, DNA, and RNA derivatives, among others. Based on inkjet printing, the invention uses inks comprising the biologic(s) included in a nanosystem, particularly in polymeric nanoparticles. | 2022-09-08 |
| 20220280441 | FILM WITH LATERALLY ADJOINED STRIPS FOR ADMINISTRATION OF A VACCINE - A film for administration to a mucosal membrane is provided. The film comprises a first film strip comprising a vaccine in a first film matrix comprising at least one film-forming agent, and at least one of a surfactant, emulsifier and/or a plasticizer, and a second film strip comprising an adjuvant in a second film matrix comprising at least one film-forming agent, and at least one of a surfactant, emulsifier and/or a plasticizer. The first and second strips of the film are laterally adjoined along an edge of the first and second strips to provide a single layer film in which the vaccine and adjuvant are not admixed prior to administration. | 2022-09-08 |
| 20220280442 | BIO-INSPIRED TISSUE-ADHESIVE HYDROGEL PATCH AND USES THEREOF - The present disclosure relates to a catechol group- or pyrogallol group-functionalized biocompatible polymer hydrogel patch having excellent biocompatibility and tissue adhesion, and uses for drug delivery, cell transplantation and tissue regeneration using the same. The biocompatible polymer hydrogel patch functionalized with the catechol group or pyrogallol group of the present disclosure has remarkably excellent mechanical properties and tissue adhesion compared with a solution-based bulk hydrogel. Therefore, it can load cells and a drug in vivo for a long time and also safely and efficiently deliver the cells and the drug to a target site. | 2022-09-08 |
| 20220280443 | Transdermal Delivery System - A system for the transdermal delivery of drugs, vitamins, or micronutrients over a time interval of up to one month. The transdermal delivery system employs a plurality of varying diameter bioactive glass capsules configured to react with water in the bloodstream to break down and release a contained dose of a drug, vitamin, or other micronutrients. The bioactive glass capsules are microscopic and able to be absorbed through the skin. An adhesive bandage is adhered to the skin via an adhesive layer. A concealed membrane is positioned centrally on an inner surface of the adhesive bandage and separated by a barrier layer. The bioactive glass capsules are housed within the concealed membrane until the patch is placed on the skin allowing them to absorb through the skin to deliver up to a month's dose of the drug, vitamin, or other micronutrients into the bloodstream. | 2022-09-08 |
| 20220280444 | Compositions Comprising Decarboxylated Cannabinoids - Various aspects of this disclosure relate to compositions comprising (i) one or more decarboxylated cannabinoids and (ii) either (a) cellulose I, (b) nucleic acids that comprise one or more nucleotide sequences that encode a geranyl-pyrophosphate-olivetolic acid geranyltransferase, (c) protein that comprises one or more amino acid sequences that encode a geranyl-pyrophosphate-olivetolic acid geranyltransferase, (d) two of a, b, and c, or (e) each of a, b, and c. | 2022-09-08 |
| 20220280445 | LOW MOISTURE RAPIDLY DISINTEGRATING ORAL DISSOLVABLE FILM - The present invention provides for an oral dissolvable film that includes a rapidly dissolving binder, a film forming polymer, a moisture deterring polymer, and at least one of a first active ingredient and a second active ingredient. Also provided is a method of forming an oral dissolvable film and kits that include the oral dissolvable film. Also provided is a method of delivering one or more active ingredients to a subject that include orally administering the oral dissolvable film. | 2022-09-08 |
| 20220280446 | STABLE CANNABINOID FORMULATIONS - The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use. | 2022-09-08 |
| 20220280447 | COMPOSITIONS AND METHODS FOR IMPROVING BRAIN FUNCTION - Brain function may be improved by administering a therapeutically effective amount of 1,3-butanediol, selected from R-1,3-butanediol, S-1,3-butanediol, and racemic 1,3-butanediol, in combination with a therapeutically effective amount of cannabidiol (CBD). The disclosed compositions include synergistically effective amounts of 1,3-butanediol in combination with a synergistically effective amount of cannabidiol (CBD). The compositions may be administered to a subject for treating anxiety, concussion, traumatic brain injury (TBI), and/or cognitive impairment. | 2022-09-08 |
| 20220280448 | USES OF CURCUMINOID COMPOSITIONS - The present invention relates to methods and uses of compositions comprising curcumin; in particular, methods and uses relating to improving the bioaccessibility, bioavailability, bioefficacy and/or bioactivity of curcuminoids in mammals. | 2022-09-08 |
| 20220280449 | CURCUMINOID COMPOSITIONS - The present invention relates to compositions comprising curcuminoids; in particular, compositions comprising curcuminoids that are highly water soluble. The present invention also relates to processes for providing such compositions and uses of such compositions. | 2022-09-08 |
| 20220280450 | PREVENTION AND TREATMENT OF CORONAVIRUS AND RELATED RESPIRATORY INFECTIONS - The present disclosure relates to compositions comprising copper-depriving compounds, including copper chelators, useful for the prophylaxis and treatment of SARS-CoV-2, SARS-CoV-2 variants and mutations, and other coronavirus infections. | 2022-09-08 |
| 20220280451 | TREATMENT OF COPPER DISORDER - The present disclosure relates to compositions comprising fixed doses of triethylenetetramine disuccinate, and methods for their use in the prophylaxis and treatment of copper-related diseases, disorders and conditions. | 2022-09-08 |
| 20220280452 | METHODS AND COMPOSITIONS FOR TREATING SMITH-MAGENIS SYNDROME - The present invention is based on the finding that subanesthetic doses of N-methyl-D-aspartate (NMDA) receptor antagonists alleviate social interaction deficits associated with behavioral disorders, such as Smith-Magenis Syndrome (SMS). The invention therefore provides methods and compositions for treating SMS. Also provided are methods of selecting NMDA receptor agonists useful in alleviating social interaction deficits associated with such behavioral disorders. | 2022-09-08 |
| 20220280453 | Pharmaceutical Formulation - The present invention relates to films comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and a compound of Formula (I), such as ketamine, or a pharmaceutically acceptable salt thereof. The present invention further relates to methods for manufacturing such films, and the use of such films in anesthesia, pain management, and the treatment of disease, in particular amnesia, depression and bipolar disorder. | 2022-09-08 |
| 20220280454 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND SYNDROMES OF AGING - Disclosed are methods for the removal of plaques containing amyloid beta, protecting the brain from amyloid beta toxicity, and restoring neurological function by the expansion of neural stem cell pools and improving mitochondrial health. | 2022-09-08 |
| 20220280455 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS FOR USE IN EPILEPSY OR SEIZURES - The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels. | 2022-09-08 |
| 20220280456 | LACOSAMIDE PHARMACEUTICAL COMPOSITION AND DOSAGE FORM THEREOF - A dosage form of lacosamide and a pharmaceutical dosage form thereof is disclosed. The dosage form includes an extended release portion and optionally an immediate release portion. Also provided are methods of providing extended release of lacosamide and treatment of a neurological or psychiatric disease or condition. | 2022-09-08 |
| 20220280457 | ORAL PHARMACEUTICAL IMMEDIATE RELEASE COMPOSITION AND METHOD OF TREATMENT FOR WEIGHT LOSS - There is disclosed an oral pharmaceutical composition for the treatment of multiple diseases comprising a denatonium cation salt and a sour anion selected from the group consisting of acetate (DA), citrate (DC) tartrate (CT), maleate (DM) and combinations thereof (collectively “denatonium salt”) and pharmaceutical excipients for gastric release of the denatonium salt. There is further disclosed an oral immediate release pharmaceutical composition to substantially release an API (active pharmaceutical ingredient) in the gastric area of the GI tract formulation, wherein the API comprises an effective amount of the denatonium salt. Preferably, the oral immediate release pharmaceutical formulation comprises from about 0.5 g to about 5 g of the denatonium salt delivering a daily dose of the denatonium salt from about 20 mg to about 150 mg to a human adult. | 2022-09-08 |
| 20220280458 | Topical Composition for and Method of Preventing and Treating Pressure Sores and Skin Irritation - Compositions of matter and methods for applying the compositions to a skin surface for prevention of and treatment of bed sores as a foamed topical cleanser including about one part by volume of diluted acetic acid (5% (w/v) aqueous solution); about one part by volume of Aloe leaf juice; and about at least | 2022-09-08 |
| 20220280459 | SUBSTITUTED FATTY ACIDS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS - The present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (II): | 2022-09-08 |
| 20220280460 | METHODS AND COMPOSITIONS FOR STIMULATING EXOSOME SECRETION - Disclosed herein are methods for improving exosome production or stimulating exosome secretion by cells. The methods comprise inhibiting at least one step of the glycolytic pathway by contacting the cells with at least one glycolytic inhibitor and/or inhibiting mitochondrial function by contacting the cells with at least one inhibitor of mitochondrial function. | 2022-09-08 |
| 20220280461 | SOLID ORAL DOSAGE FORM COMPRISING NAPROXEN AND VITAMIN B12 - The present invention relates to a solid oral dosage form comprising naproxen and vitamin B12. Preferably, it is a solid oral dosage form for use in the treatment of pain such as low back pain. It is a fixed-dose combination (FDC) which increases patient compliance. The method of preparing such solid oral dosage form comprises the extragranular addition of vitamin B12 to an intragranular composition, wherein said intragranular composition comprises naproxen or a pharmaceutically acceptable salt thereof and at least one binder. | 2022-09-08 |
| 20220280462 | SOLID ORAL DOSAGE FORM COMPRISING NAPROXEN AND VITAMIN B1 - The present invention relates to a solid oral dosage form comprising naproxen and vitamin B1. Preferably, it is a solid oral dosage form for use in the treatment of pain such as low back pain. It is a fixed-dose combination (FDC) which increases patient compliance. The method of preparing such solid oral dosage form comprises the preparation of naloxone granules, the intragranular addition of vitamin B1 and optionally the extragranular addition of other B-vitamins such vitamin B6 and vitamin B12. | 2022-09-08 |
| 20220280463 | PHARMACEUTICAL FORMULATIONS COMPRISING DICLOFENAC - Conventional injectable formulations of Diclofenac are known to have excipients which cause irritation at the site of injection and are painful. Further, such conventional formulations also cause thrombophlebitis. Other injectable formulations of Diclofenac known in the prior art also contain excipients which are tissue irritants and may cause toxicity when administered through intravenous route. The cyclodextrin compounds used in Dyloject® may cause problems while elimination in the renal compromised patients. The present invention therefore provides injectable Diclofenac formulations which do not cause irritation and pain at the site of injection. Further, the formulations of the present invention do not include cyclodextrins, therefore can also be administered to the renal compromised patients. | 2022-09-08 |
| 20220280464 | Effects of Heparin on Topical Use of Plasters Containing a Non-Steroidal Anti-Inflammatory Drug - The present invention provides for a method of improving the release of non-steroidal anti-inflammatory drugs (NSAIDs) from a plaster or bandage comprising an adhesive layer with a pharmaceutically acceptable NSAID together with heparin or a heparinoid. The invention also provides for methods of reducing muscle hyperalgesia in subjects without spontaneous pain. | 2022-09-08 |
| 20220280465 | USES OF LONG-CHAIN POLYUNSATURATED FATTY ACIDS - The present invention is directed to methods of acutely improving or enhancing cardiovascular and/or cognitive function, comprising the administration of LCPUFAs, in particular docosahexanoic acid (DHA), uses and compositions thereof. | 2022-09-08 |
| 20220280466 | Memory in subjects with mini-mental state examination of 24-26 - The invention thus pertains to the use of a composition comprising: (a) uridine or uridine phosphate; and (b) docosahexaenoic acid and/or eicosapentaenoic acid, for improving memory and/or the treatment or prevention of impaired memory function, in a subject with a mini-mental state examination of 24-26, wherein said composition is enterally administered to the subject. In the MMSE test, any score of 27 or higher (out of 30) is effectively normal. In the patients with dementia, 20-26 indicates mild dementia, 10-19 moderate dementia, and below 10 severe dementia. It was the present inventors' belief that within the group of 20-26, the memory impairment in the sub-group of 24-26 may even be reversible, as the pathological pathways have just started to develop. In this group of subjects the pathological pathways have just started to develop. Clinical studies show excellent results for this subgroup. | 2022-09-08 |
| 20220280467 | METHODS AND COMPOSITIONS FOR TREATING INFECTION AND INFLAMMATION WITH SELENOCYANATE - The present invention generally relates to methods and compositions for treating pulmonary infections and inflammation with a composition comprising selenocyanate, hyposelenocyanite or a selenocyanate conjugate. | 2022-09-08 |
| 20220280468 | METHOD FOR PREVENTING OCCURRENCE OF CARDIOVASCULAR EVENT IN MULTIPLE RISK PATIENT - Disclosed is method using a composition is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient. | 2022-09-08 |
| 20220280469 | PHARMACEUTICAL COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF - Disclosed are a drug-carrier complex and a preparation method therefor and use thereof. The drug-carrier complex comprises an active ingredient and a carrier, wherein the carrier is albumin, the active ingredient is loaded on the carrier, and the active ingredient is a platinum-based drug. Compared with free platinum-based drugs, the drug-carrier complex can significantly extend in vivo half-life of the platinum-based drug, improve in vivo tissue distribution of the platinum-based drug, increase tissue selectivity of the platinum-based drug, reduce damage to normal tissues and systemic toxicity of the platinum-based drug, and thus improve therapeutic effect. | 2022-09-08 |
| 20220280470 | TREATMENT FOR TUMORS DRIVEN BY METABOLIC DYSFUCTION - The present disclosure relates to modified or polymer conjugated MetAP2 inhibitors. The present disclosure also relates to methods of treating metabolically-driven diseases and disorders, such as certain cancers. | 2022-09-08 |
| 20220280471 | Treatment of Affective Disorders - Embodiments of the invention relate generally to the treatment of affective disorders and, more particularly, to the treatment of affective disorders in a patient of Majority Black African ancestry. | 2022-09-08 |
| 20220280472 | TREATMENT OF PULMONARY FIBROSIS USING INHIBITORS OF NEU1 SIALIDASE - The present invention provides a method for treating a fibrotic lung disease or fibrotic lung condition in a subject that involves an increase in NEU1 expression and/or activity, comprising administering to the subject an effective amount of an agent that inhibits the activity of NEU 1 sialidase, thereby treating the fibrotic lung disease or fibrotic lung condition in the subject. | 2022-09-08 |
| 20220280473 | COMPOSITIONS AND METHODS FOR MODULATING EPITHELIAL-MESENCHYMAL TRANSITION - The inventions relate to the use of anti-hemichannel compounds, including anti-connexin 43 hemichannel opening compounds, inhibitors and blockers, to modulate, suppress and stabilize epithelial-mesenchymal and/or endothelial-mesenchymal transition in diseases, disorders and conditions, including fibrotic diseases, disorders and conditions and other conditions associated with fibrosis. | 2022-09-08 |
| 20220280474 | KV1.3 ANTAGONISTS FOR USE IN THE TREATMENT OF CHRONIC AND ACUTE PAIN - The present patent application relates to the use of antagonists of delayed rectifier potassium (K | 2022-09-08 |
| 20220280475 | COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING NEURODEGENERATIVE DISEASES AND COGNITIVE DISORDERS - Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress. | 2022-09-08 |
| 20220280476 | KCNT1 INHIBITORS AND METHODS OF USE - The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein. | 2022-09-08 |
| 20220280477 | Compositions And Methods For Treating Traumatic Brain Injury - The present invention relates, in certain embodiments, to methods for preventing and/or treating neurodegenerative damage (e.g., secondary cascade of neurodegenerative damage) and improving functional outcomes (e.g., outcomes associated with cognitive, behavior and sensorimotor function) caused by traumatic brain injury (TBI) using neuroprotective lipoyl compounds. The present invention also provides, in various embodiments, compositions for use in treating and/or preventing TBI in a subject in need thereof, compounds for use in the manufacture of a medicament for treating and/or preventing TBI in a subject in need thereof, and methods of preparing a pharmaceutical composition for treating and/or preventing secondary brain damage caused by TBI. | 2022-09-08 |
| 20220280478 | METHODS OF USING RIFAMYCIN SV FOR THE TREATMENT OF SICKLE CELL DISEASE - Provided herein is the use of rifamycin SV the treatment of sickle cell disease (SCD). | 2022-09-08 |
| 20220280479 | SELF-EMULSIFYING FORMULATIONS OF DIM-RELATED INDOLES - Disclosed herein are self-emulsifying compositions and formulations of Diindolylmethane (“DIM”) and certain derivatives of DIM, their uses and methods of making. In particular, the disclosed compositions comprise a DIM-related indole as an active agent and a carrier, wherein the carrier comprises a solvent, one or more surfactants with an HLB of greater than 7, and one or more co-surfactants with an HLB equal to or less than 7. In certain aspects of the invention, the compositions disclosed herein show improved bioavailability. | 2022-09-08 |
| 20220280480 | SULCARDINE ADMINISTRATION FOR TREATMENT OF ACUTE ATRIAL FIBRILLATION - Provided herein are compositions and methods for administration of sulcardine to a subject in need thereof. | 2022-09-08 |
| 20220280481 | METHODS OF TREATING GENERALIZED PUSTULAR PSORIASIS WITH AN ANTAGONIST OF CCR6 OR CXCR2 - The present disclosure provides, inter alia, methods of treating generalized pustular psoriasis (GPP) by administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist. Also provided herein are methods of modulating dysregulated IL-36 signaling in a subject in need thereof and methods of reducing neutrophil, inflammatory dendritic cell (iDC), and/or CD4 T cell accumulation in a subject in need thereof, said methods, include dministering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist. In some embodiments, the CCR6 and/or CXCR2 antagonist has the formula: | 2022-09-08 |
| 20220280482 | FORMULATIONS OF PSILOCIN THAT HAVE ENHANCED STABILITY - A composition of psilocin that is stable including at least one agent or chemical modification that provides enhanced stability. A method making stable psilocin, by providing a formulation of psilocin including at least one agent or chemical modification that provides enhanced stability. A method of treatment of a disease or condition, by administering a composition of psilocin that is stable to an individual, and treating the disease or condition. | 2022-09-08 |
| 20220280483 | METHODS AND USES FOR APELIN RECEPTOR AGONISTS - The present disclosure provides a method for treating idiopathic pulmonary fibrosis in a patient in need thereof comprising administering a therapeutically effective amount of an apelin receptor agonist. | 2022-09-08 |
| 20220280484 | NOVEL USE - The present invention provides a method of prophylaxis or treatment of a senescence-associated disease or disorder by administering to a subject in need thereof, a therapeutically effective amount of a NMT inhibitor. | 2022-09-08 |
| 20220280485 | HODGKIN LYMPHOMA THERAPY - There is provided a compound of formula I or a pharmacologically acceptable salt thereof for use in a method of treating Hodgkin lymphoma in a patient in need thereof comprising administering to said patient an effective amount of said compound of formula I or a pharmacologically acceptable salt thereof: | 2022-09-08 |
| 20220280486 | COMBINED CANCER THERAPY INVOLVING CHEMICAL ACTIVATION OF INTEGRINS AND TARGETED CELL IMMUNOTHERAPY - The present disclosure relates generally to novel approaches to activate integrin signaling in order to overcome CD47 checkpoint inhibition and to promote macrophage phagocytic signaling pathway. The disclosure also provides methods and compositions for treatment of cancer, including solid tumor and hematologic malignancy, by promoting macrophage-mediated engulfment of cancer cells. Use of integrin activation in combination with adoptive transfer of engineered macrophages to increase engulfment of cancer cells is also provided. | 2022-09-08 |
| 20220280487 | INHIBITION OF MYCOBACTERIAL TYPE VII SECRETION - The invention relates to compounds and pharmaceutically acceptable salts thereof, and to their medical use. Exemplary medical uses are the prevention and treatment of a bacterial infection, for example, a mycobacterial infection, such as a | 2022-09-08 |
| 20220280488 | PHARMACEUTICALLY ACTIVE PYRAZOLO-PYRIDONE MODULATORS OF DCN1/2-MEDIATED CULLIN NEDDYLATION - A DCN1/2-mediated cullin neddylation modulator; a method for treating disorders associated with dysfunctional DCN1 and/or UBC12, Alzheimer's disease, other neurodegenerative diseases, bacterial infections, or viral infections; and a method for treating cancers are provided. The DCN1/2-mediated cullin neddylation modulator includes a compound according to Formula I disclosed herein. The methods include administering to a mammal a therapeutically effective amount of a compound according to Formula I. Also provided herein is a pharmaceutical composition including a therapeutically effective amount of a compound according to Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. | 2022-09-08 |
| 20220280489 | COMBINATION THERAPY FOR CANCER USING AZABICYCLIC COMPOUND AND POLY(ADENOSINE 5'-DIPHOSPHATE-RIBOSE) POLYMERASE INHIBITOR - Provided is a novel method for treating cancer with a high antitumor effect. The present invention provides an antitumor agent comprising an azabicyclo compound of the following Formula (I) or a salt thereof and a poly(adenosine 5′-diphosphate-ribose) polymerase inhibitor which are administered in combination. | 2022-09-08 |
| 20220280490 | TREATMENT OF FRAGILE X SYNDROME - The present invention relates to a composition comprising ibudilast, or a pharmaceutically acceptable salt thereof, for use in the treatment of Fragile X syndrome, wherein the composition does not comprise sulindac, or a pharmaceutically acceptable salt thereof, or bumetanide, or a pharmaceutically acceptable salt thereof. | 2022-09-08 |
| 20220280491 | SEPTIN INHIBITORS FOR TREATMENT OF CANCERS - The present disclosure provides novel compounds, compositions, and methods for modulating one or more septin proteins, e.g., septin-2. Such compounds and compositions are useful for the treatment of a cancer, e.g., endometrial, pancreatic, lung, breast or ovarian cancer, such as serous and ovarian clear cell carcinoma. | 2022-09-08 |
| 20220280492 | THERAPEUTIC AGENT FOR CANCER HAVING RESISTANCE TO ANTI-CCR4 ANTIBODY - An object of the present invention is to provide a therapeutic agent having an excellent effect on ATL patients with a history of treatment with an anti-CCR4 antibody, in other words, ATL patients who developed resistance to an anti-CCR4 antibody. An EZH1/2 dual inhibitor, a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof was found to have an excellent effect on anti-CCR4 antibody-resistant cancer (particularly mogamulizumab-resistant cancer). | 2022-09-08 |
| 20220280493 | TREATMENT OF A RESPIRATORY CORONAVIRUS INFECTION WITH NITROXIDES - The use of nitroxide and nitrone compounds for the treatment of acute, breakthrough, or “long-haul” respiratory coronavirus infections is claimed. Exemplars include Tempol and its reduced prodrug hydroxylamine form as well as PBN (N-Benzylidene-tert-butylamine N-oxide). Methods of administration include nasal insufflation, inhalation, topical to skin or mucosa, orally, intradermally, subcutaneously, by intravenus infusion, using suitable pharmacologically-active formulations. | 2022-09-08 |
| 20220280494 | COMPOSITIONS FOR SMALL MOLECULE THERAPEUTIC AGENT COMPOUNDS - A composition comprising a small molecule therapeutic agent and a polyprotic acid compound or a mixture of two monoprotic acid compounds is described. The polyprotic acid is present in an amount that (i) is equal to or less than the molar amount of the therapeutic agent and (ii) provides a total number of acid hydrogens that exceeds the stoichiometric equivalent for the molar amount of therapeutic agent. The two or more monoprotic acids are present such that each monoprotic acid is in an amount that is equal to or less than the molar amount of the therapeutic agent and together the two or more monoprotic acids provide a total number of acid hydrogens that exceeds the stoichiometric equivalent for the molar amount of therapeutic agent. The polyprotic acid or mixture of monoprotic acids provide a composition that delivers the therapeutic agent for a sustained period of time. | 2022-09-08 |
| 20220280495 | Combination Therapy Including an MDM2 Inhibitor and One or More Additional Pharmaceutically Active Agents for the Treatment of Cancers - The present invention provides combination therapy that includes an MDM2 inhibitor and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers. | 2022-09-08 |
